Last night, Intellia filed a material event report ( 8-k ) with the SEC.  In there, they revealed a case of very high, grade 4 liver enzyme...

There is widespread consternation about the disconnect between recent clinical breakthroughs and the performance of CRISPR-related stocks.  ...

Prime Medicine disclosed this week that they were in binding arbitration with Beam Therapeutics regarding their development of prime editin...